stoxline Quote Chart Rank Option Currency Glossary
Atossa Therapeutics, Inc. (ATOS)
1.57  -0.04 (-2.48%)    05-17 16:00
Open: 1.6
High: 1.6
Volume: 805,576
Pre. Close: 1.61
Low: 1.55
Market Cap: 197(M)
Technical analysis
2024-05-17 4:44:05 PM
Short term     
Mid term     
Targets 6-month :  2.11 1-year :  2.46
Resists First :  1.8 Second :  2.11
Pivot price 1.58
Supports First :  1.45 Second :  1.24
MAs MA(5) :  1.55 MA(20) :  1.56
MA(100) :  1.26 MA(250) :  1.02
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  46.6 D(3) :  40.8
RSI RSI(14): 49.6
52-week High :  2.3 Low :  0.62
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ATOS ] has closed above bottom band by 44.5%. Bollinger Bands are 21.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.6 - 1.61 1.61 - 1.62
Low: 1.53 - 1.54 1.54 - 1.55
Close: 1.55 - 1.57 1.57 - 1.59
Company Description

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Headline News

Fri, 17 May 2024
Atossa Therapeutics, Inc. Forecasted to Post Q2 2024 Earnings of ($0.05) Per Share (NASDAQ:ATOS) - Defense World

Thu, 16 May 2024
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Update - MarketBeat

Thu, 16 May 2024
Q2 2024 EPS Estimates for Atossa Therapeutics, Inc. Increased by Analyst (NASDAQ:ATOS) - MarketBeat

Wed, 15 May 2024
Atossa Therapeutics gives final dose in breast cancer prevention study - Proactive Investors Australia

Wed, 15 May 2024
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial - GlobeNewswire

Wed, 15 May 2024
Atossa Therapeutics' (ATOS) Overweight Rating Reaffirmed at Cantor Fitzgerald - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 125 (M)
Shares Float 117 (M)
Held by Insiders 0 (%)
Held by Institutions 19.2 (%)
Shares Short 11,440 (K)
Shares Short P.Month 10,560 (K)
Stock Financials
EPS -0.24
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.73
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -17.9 %
Return on Equity (ttm) -28.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.26
Qtrly Earnings Growth 0 %
Operating Cash Flow -21 (M)
Levered Free Cash Flow -12 (M)
Stock Valuations
PE Ratio -6.55
PEG Ratio 0
Price to Book value 2.15
Price to Sales 0
Price to Cash Flow -9.4
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android